Hepatitis C treatment proven effective but linked to SJS
PEGASYS, a new medication proven effective in the treatment of hepatitis C for Latino patients caused a severe adverse skin reaction known as erythema multiforme major, or Stevens Johnson Syndrome (SJS), in patients during post-approval use, according to Cloud Computing Journal. The article referenced a study published in the New England Journal of Medicine.
The study is the largest conducted to-date focusing on Latino patients with the hepatitis C virus. The virus is a blood-borne infectious disease of the liver that can lead to cirrhosis, liver cancer and the need for liver transplants. Hepatitis C is reported to affect Latino patients differently than non-Latino patients. The Latino population is the largest-growing minority in the United States and has a higher prevalence of hepatitis C. The virus also has a faster progression and a much higher mortality among Latinos than non-Latinos.
PEGASYS is produced by New Jersey-based Hoffman-La Roche Inc. It can be used alone or in combination with COPEGUS, for the treatment of adults with chronic hepatitis C who have compensated liver disease. The medication was found most effective in patients with compensated liver disease and histological evidence of cirrhosis.
However, erythema multiforme major, also known as SJS, was reported among the serious adverse events that occurred during post-approval use of PEGASYS therapy. SJS is a rare but life-threatening reaction to medication that begins as a rash that blisters over, causing the skin to peel off in sheets. It also affects the mucus membranes, such as eyes, mouth and vagina, which can blister over and lead to dehydration, infection and serious eye problems such as blindness. More than 200 medications have been linked to SJS.
If you experience a rash or blistering while taking PEGASYS or any other medication, healthcare officials advise you contact your doctor and go to the emergency room.
Related posts:
